1. Introduction {#sec1-nutrients-10-00550}
===============

Celiac disease is a common chronic small bowel disease caused by intolerance to gluten found in foods containing wheat, rye or barley \[[@B1-nutrients-10-00550]\]. It has been debated whether the global differences in prevalence are due to variations in infant feeding practices \[[@B2-nutrients-10-00550]\]. One affecting factor could be variations in gluten intake during the first years of life \[[@B3-nutrients-10-00550]\]. The effects of dairy product intake on the risk of celiac disease is less studied. Although the vast majority of patients with celiac disease have antibodies directed against tissue transglutaminase (tTGA) \[[@B4-nutrients-10-00550]\], a proportion also have detectable antibodies against milk protein \[[@B5-nutrients-10-00550]\]. Although a recent study did not find avoidance of cow´s milk-based products to protect from celiac disease compared with extensively hydrolyzed formula \[[@B5-nutrients-10-00550]\], it is not entirely clear whether other components in milk products may trigger celiac disease.

Commercial instant porridges and cereal milk drinks based on milk powder and gluten containing cereals are common infant food products in some parts of the world \[[@B6-nutrients-10-00550]\]. In milk powder production, advanced glycation end products (AGEs) are formed through Maillard reactions \[[@B7-nutrients-10-00550]\]. AGEs have pro-inflammatory effects and may induce increased oxidative stress in adults \[[@B8-nutrients-10-00550]\]. Notably, levels of AGEs increase during storage of commercial instant porridge and cereal milk drinks in room temperatures \[[@B9-nutrients-10-00550]\]. It could therefore be hypothesized that a high intake of commercial instant porridge and cereal milk drinks containing high concentrations of AGEs cause an initial inflammation that results in an increased gut permeability to gluten antigens that eventually leads to celiac disease in genetic at risk individuals.

The aim of this study was to investigate if intake of milk powder is associated with celiac disease in children. We prospectively collected food data from a birth cohort of genetically predisposed children that later developed celiac disease and compared it to matched controls in a nested case-control study.

2. Subjects and Methods {#sec2-nutrients-10-00550}
=======================

2.1. Study Population {#sec2dot1-nutrients-10-00550}
---------------------

The Environmental Determinants of Diabetes in the Young (TEDDY) study is an observational study conducted at 6 clinical centers in Finland, Germany, Sweden and the United States, investigating the environmental factors associated with type 1 diabetes and celiac disease \[[@B10-nutrients-10-00550]\]. Children carrying any of the HLA genotypes associated with type 1 diabetes and celiac disease were invited to participate in a 15-year follow-up \[[@B10-nutrients-10-00550]\], and among the enrolled participants 2525 were from the Swedish site. The TEDDY study is monitored by the National Institutes of Health and has been approved by ethics review boards at individual sites and informed consent from a parent or primary caretaker were obtained prior to screening.

2.2. Screening for Celiac Disease {#sec2dot2-nutrients-10-00550}
---------------------------------

Annual screening for celiac disease begins at 2 years of age by measurement of IgA and IgG autoantibodies against tTGA using radioligand binding assays as previously described \[[@B1-nutrients-10-00550]\]. Children positive for tTGA have their blood samples analyzed to determine the closest time point of tTGA seroconversion. Children positive for tTGA in two consecutive samples were evaluated for celiac disease at their health care provider. Diagnosis of celiac disease was established if a child had a biopsy showing Marsh score of 2 or higher and responded to a gluten-free diet with a significant decrease in tTGA levels.

As of July 31 in 2016, 2,077 Swedish TEDDY children had been screened for tTGA of whom 504 (24%) were tTGA positive at median 30 months of age (first quartile (Q1): 21, third quartile (Q3): 53) and 85 of those (17%) children seroconverted to tTGA prior to or at 24 months of age. Among the 238 tTGA positive children that were finally investigated with an intestinal biopsy, 207 of the 2077 (10%) children were diagnosed with celiac disease at median 45 months of age (Q1: 33, Q3: 70) ([Figure 1](#nutrients-10-00550-f001){ref-type="fig"}).

2.3. Study Design {#sec2dot3-nutrients-10-00550}
-----------------

A nested case-control design included the 207 cases with biopsy-proven celiac disease and 3 controls randomly selected from the cohort for each case after matching on gender, the number of HLA DQ2 alleles and birth year (i.e., 1--3 nested case-control design) ([Table 1](#nutrients-10-00550-t001){ref-type="table"}). All controls were free of biopsy-proven celiac disease within 3 months of the matched case's age of biopsy, as well as tTGA negative within 3 months of the matched case's age of seroconversion. In this nested case-control study, 39 cases were selected as controls until seroconversion of tTGA.

2.4. Dietary Assessment {#sec2dot4-nutrients-10-00550}
-----------------------

A study nurse collected a 24-h dietary recall at the first visit between 3 and 4.5 months of age. Three-day food records, including two weekdays and one weekend day, were then collected at follow-up visits at 6 months, 9 months, 12 months, 18 months, and 24 months of age, respectively. Normal food habits were encouraged during the time of the food record collection. Parents were provided with a manual including written instructions, as well as photos of portion sizes and drawings of foods of different sizes and as reference. When the child started daycare, a set of separate food record sheets and manual were provided for the daycare personnel. At the study visits, the study nurse performed a face-to-face interview, probing for missing or unclear information and revising the food record accordingly. A trained study dietitian or nutritionist entered the dietary information in a food database. The TEDDY database for Sweden was based on the Swedish National Food Composition Database, with information about nutrient content for foods and standard recipes for several composite dishes \[[@B11-nutrients-10-00550]\]. Products and brands different from standard food items in ingredients or nutritional values as well as unique recipes recorded by families were added to the database. For commercial baby foods, recipes were created based on the ingredient list together with information on the nutritional value, and added as a new food item if it changed in nutritional value or content. The study personnel entering the food data reached consensus estimates for the weight of foods when there was no information in the national food database or from the producer.

Intake of milk powder was either obtained directly from the database (including infant cereal milk drink and instant porridge), as an estimate for average content in a food type (including infant formula and chocolate) or an estimate based on brand name (including yoghurts). Based on the structure of the database, the content of milk powder could not be estimated for some specific products (such as ice cream, powder-based sauces, and certain prepared foods). From the dietary records, gluten intake was also assessed as it was considered a confounding factor. Total intake of wheat, rye and barley could be obtained from the database, and the amount of ingested gluten was calculated by multiplying the analyzed content of protein in each of these grains with 0.8 for wheat, 0.65 for rye, and 0.5 for barley \[[@B12-nutrients-10-00550]\].

Body weight was measured at every clinic visit at 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months ([Figure 2](#nutrients-10-00550-f002){ref-type="fig"}a). Scales were of different brands over the study period of which Tanita (Tanita Corp, Tokyo, Japan) was most commonly applied. Tanita scale was the most common and that scales were calibrated regularly. Energy intake for breastfed subjects was estimated using the energy requirement based on the child's age and weight at the time for the food record, then subtracting the energy intake from other reported food ([Figure 2](#nutrients-10-00550-f002){ref-type="fig"}b) \[[@B13-nutrients-10-00550]\].

2.5. Statistical Analysis {#sec2dot5-nutrients-10-00550}
-------------------------

Daily intake of milk powder in grams per day was assessed as the mean intake from the three-day diet records. Intake data were available until 24 months of age, but age of tTGA seroconversion for cases ranged from 10 to 120 months. Only available intakes reported prior to the case's tTGA seroconversion were included in analysis in order to compare between a case and matched control, using conditional logistic regression. Daily intake was also analyzed in grams per kilogram body weight (g/kg/day) in order to standardize intake between subjects. Intake reported at the visit prior to the case's tTGA seroconversion was as "last intake," and the sum of all intakes assessed as "total intake." Intake at a given age (3 months, 6 months, 9 months, 12 months, 18 months, or 24 months) was compared if it was available or appropriate for the case's age of seroconversion. We first adjusted for having a first-degree relative with celiac disease as a confounder. Milk powder intake was then analyzed with and without adjustment for gluten intake in order to separate the effect on risk of celiac disease between the two dietary exposures. Odds ratios were reported with 95% confidence intervals (CI), along with two-sided p-value. Statistical significance was determined when *p*-value \<0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-nutrients-10-00550}
==========

Energy intake and body weight increased as expected with age for both cases and controls ([Figure 2](#nutrients-10-00550-f002){ref-type="fig"}a,b). The mean daily intake of milk powder increased in both cases and controls by 12 months of age and more significantly between 6 months and 9 months of age, respectively ([Figure 2](#nutrients-10-00550-f002){ref-type="fig"}c). At 6 months, the intake of milk powder was 15.9 g and 15.3 g per day for cases and controls respectively. At 9 months it had increased to 28.1 grams and 25.4 grams per day for cases and controls and at 24 months it had decreased to 13.3 grams and 14.7 grams per day for cases and controls.

Neither energy intake nor body weight were associated with celiac disease. Intake of milk powder in grams per day prior to seroconversion of tTGA positivity did not increase the risk of celiac disease, either for last intake, nor total intake or for intake at any given age. This was also true for the relative intake in grams per kg body weight ([Table 2](#nutrients-10-00550-t002){ref-type="table"}). In the unadjusted model, there was a small increased risk for celiac disease for the milk powder intake at 9 months of age in grams per day (OR = 1.01, 95%CI = 1.0--1.02; *p* = 0.037), as well as in grams per kilogram bodyweight per day (OR = 1.1, 95%CI = 1.0--1.2; *p* = 0.044).

Having a first-degree relative with celiac disease (OR = 2.53, 95%CI 1.37, 4.67, *p* = 0.003) and reported gluten intake when assessed in grams per day (OR = 1.09, 95%CI 1.03--1.16; *p* = 0.004) as well as in grams per kilograms per day (OR = 2.73, 95%CI 1.36--5.49; *p* = 0.005) were associated with celiac disease. When these confounders were included the adjusted model, the association between milk powder intake and celiac disease no longer remained significant.

4. Discussion {#sec4-nutrients-10-00550}
=============

The present study showed that intake of milk powder does not increase the risk of celiac disease in genetically susceptible Swedish children. The peak intake of milk powder was observed at the age of 9 months after which it started to decrease, and may reflect a dietary intake pattern of formula, commercial porridge and milk cereal drink. The intake of milk powder observed was equivalent to the amount of commercial porridge and cereal milk drink consumed by Swedish infants as reported in a previous study \[[@B6-nutrients-10-00550]\].

The strength of the dietary assessment methods used in this study is that they allow for estimations of individual intake of foods. Repeated food records measure changes in dietary habits of infants and growing young children over time and is a suitable method when studying dietary intake and risk of disease \[[@B14-nutrients-10-00550]\]. Another advantage with the dietary data collected for this study is minimization of recall bias, which has been a limitation in previous studies using retrospective dietary assessment methods \[[@B15-nutrients-10-00550],[@B16-nutrients-10-00550]\]. A prospective study design has the advantage of unawareness of the tTGA status at the time of the food data collection, which otherwise may influence parents to change their child's diet.

Analysis of relative dietary intake we also made, as recommended in nutrition research and disease \[[@B17-nutrients-10-00550]\]. The energy requirement of a child depends on age, weight, and growth \[[@B13-nutrients-10-00550]\]. A child larger in size may consume bigger portions than their smaller counterpart, resulting in a higher nutrient intake, but not necessarily higher intake in relation to body weight. We adjusted for the confounders of having a family member with celiac disease and for the gluten intake, respectively. The adjustments had a significant impact on the results, since we found an association with increased risk for celiac disease and intake of milk powder reported at the 9-month visit. We have previously published a study on the association between amount of gluten intake and celiac disease performed on the same cohort, which showed that the last intake of every gram gluten per day before seroconversion to tTGA positivity increased the risk of celiac disease by 28% \[[@B3-nutrients-10-00550]\].

The limitations of this study includes that milk powder intake was only studied in the first 2 years of life, whereas the majority of the celiac cases were diagnosed several years later. As 15.6% of the subjects also had missing food record data at 24 months, data collected at earlier timepoints was applied for the analyses, which may affect the reliability of the results. Additionally, we did not have access to complete information on content of milk powder for all food items; therefore, estimates had to be used. Although the excluded foods were considered less commonly used in the selected age groups, estimations on possible amounts of missing data were not performed. In this study, we analyzed two dietary exposures, and some common Swedish infant products contain both. Although the statistical analyses adjusted for the gluten intake, the study could be criticized for not quantifying the amount of gluten from products that also contained milk powder.

In conclusion, this nested case-control study on intake of milk powder during the first 2 years of life in genetically susceptible children showed that consumption of milk powder is not associated with celiac disease for Swedish children.
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###### 

Body weight at clinic visit (**a**) and assessed daily mean intake of energy (kcal) (**b**), mean daily intake of milk powder (gram per day) from 3-day food records in cases with celiac disease and matched, healthy controls (1:3) (**c**). For breastfed subjects, energy intake was estimated using assessed energy requirement and subtracting energy intake from other reported food. Controls were matched to cases by gender, HLA genotype and birth year.
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###### 

Characteristics of the identified cases with celiac disease in the Swedish TEDDY birth cohort used as matching factors in a nested 1-3 case-control study.

  Matching Variable   Cases N = 207 (%)
  ------------------- -------------------
  Sex                 
  \- Female           131 (63.3)
  \- Male             76 (36.7)
  Birth year          
  \- 2004             11 (5.3)
  \- 2005             39 (18.8)
  \- 2006             28 (13.5)
  \- 2007             41 (19.8)
  \- 2008             37 (17.9)
  \- 2009             46 (22.2)
  \- 2010             5 (2.4)
  HLA-genotype        
  \- DQ2/DQ8          64 (30.9)
  \- DQ8/DQ8          35 (16.9)
  \- DQ2/DQ2          100 (48.3)
  \- Other            8 (3.9)

nutrients-10-00550-t002_Table 2

###### 

Comparison of mean daily intake of milk powder (grams per day and grams per kilo bodyweight) in cases with celiac disease and matched, healthy controls (1:3), and risk of celiac disease analyzed with conditional logistic regression expressed as odds ratio (OR) after adjusting for having a first-degree relative with celiac disease and for gluten intake at the given time point. Controls were matched to cases by gender, HLA genotype and birth year.

  Time point         Number of cases analyzed   Number of cases missing intake   Milk powder intake (g/day)   Milk powder intake (g/kg/day)                       
  ------------------ -------------------------- -------------------------------- ---------------------------- ------------------------------- ------------------- -------
  Last intake ^1^    207                        0                                1.0 (0.99--1.01)             0.937                           0.99 (0.87--1.13)   0.861
  Total intake ^2^   207                        0                                1.0 (1.0--1.00)              0.662                           1.0 (0.98--1.03)    0.763
  Intake at                                                                                                                                                       
  3 months           207                        0                                0.99 (0.97--1.01)            0.159                           0.92 (0.83--1.02)   0.125
  6 months           202                        5                                1.0 (0.99--1.02)             0.643                           1.02 (0.91--1.13)   0.788
  9 months           198                        9                                1.01 (1.0--1.02)             0.069                           1.09 (0.99--1.19)   0.072
  12 months          192                        9                                1.01 (1.0--1.02)             0.181                           1.08 (0.96--1.21)   0.184
  18 months          146                        21                               1.0 (0.98--1.02)             0.983                           1.01 (0.84--1.21)   0.923
  24 months          103                        19                               0.99 (0.97--1.01)            0.202                           0.88 (0.69--1.12)   0.301

^1^ Last reported intake at the visit prior to seroconversion of tTGA; ^2^ Sum of all reported intakes prior to seroconversion of tTGA
